


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 25, 2001

Signature: *Staci Harris*

(Staci Harris)

Docket No.: HO-P02188US0
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Goran Forsberg, et al.

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001

Examiner: Not Yet Assigned

For: A NOVEL ENGINEERED SUPERANTIGEN
FOR HUMAN THERAPY

TRANSMITTAL LETTER

Commissioner for Patents
Washington, DC 20231

RECEIVED
JAN 15 2002
OFFICE OF PETITIONS

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

1. Request for Corrected Filing Receipt
2. Copy of Filing Receipt
3. Request for Change of Entity Status
4. Fee Transmittal
5. Return postcard

The Commissioner is hereby authorized to charge the sum \$1,123.00 to our deposit account No. 06-2375, under Order No. 10104199. Any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account.

Dated: October 25, 2001

Respectfully submitted,

By *Melissa W. Acosta*

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5407

(713) 651-5246

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to: Office of Initial Patent Examination Customer Service Center, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 25, 2001

Signature:

(Staci Harris)

#15
Docket No.: HO-P02188US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Goran Forsberg, et al.

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001

Examiner: Not Yet Assigned

For: A NOVEL ENGINEERED SUPERANTIGEN
FOR HUMAN THERAPY

Office of Initial Patent Examination
Customer Service Center
Commissioner for Patents
Washington, DC 20231

RECEIVED

JAN 15 2002

OFFICE OF PETITIONS

REQUEST FOR CORRECTED FILING RECEIPT

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has an error in the entity status.

The filing status should be Large Entity.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Dated: October 25, 2001

Respectfully submitted,

By

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5407

(713) 651-5246



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/900,766	07/06/2001	1645	1163	P02188US0 (10104199)	11	92	7

CONFIRMATION NO. 7699

FILING RECEIPT



OC000000006808906

FULBRIGHT & JAWORSKI L.L.P.
Melissa W. Acosta
Suite 5100
1301 McKinney
Houston, TX 77010-3095

Date Mailed: 09/28/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).


Applicant(s)

Goran Forsberg, Eslov, SWEDEN;
Eva Erlandsson, Dalby, SWEDEN;
Per Antonsson, Lund, SWEDEN;
Bjorn Walse, Lund, SWEDEN;

Domestic Priority data as claimed by applicant

Foreign Applications

SWEDEN 0102327-4 06/28/2001



If Required, Foreign Filing License Granted 09/27/2001

Projected Publication Date: 01/02/2003

Non-Publication Request: No

Early Publication Request: No

SMALL ENTITY

Large Entity

Title

Novel engineered superantigen for human therapy

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED


No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to: Office of Initial Patent Examination Customer Service Center, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 25, 2001

Signature: Staci Harris
(Staci Harris)

Docket No.: HO-P02188US0
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Goran Forsberg, et al.

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001

Examiner: Not Yet Assigned

For: A NOVEL ENGINEERED SUPERANTIGEN
FOR HUMAN THERAPY

Adjustment date: 01/15/2002 GTEFFERA
07/13/2001 GTEFFERA 00000076 062375 09900766
01 FC:201 355.00 CR
02 FC:202 160.00 CR
03 FC:203 648.00 CR
01/15/2002 GTEFFERA 00000153 062375 09900766
01 FC:101 740.00 CH
02 FC:103 1296.00 CH
03 FC:102 336.00 CH

Special Program Law Office
Office of Petitions
Assistant Commissioner for Patents
Washington, DC 20231

REQUEST FOR CHANGE IN ENTITY STATUS

RECEIVED

Dear Sir:

JAN 15 2002

OFFICE OF PETITIONS

Applicant hereby requests that a change in entity status be issued in the above-identified patent application. The application was filed claiming small entity status. However, it was recently determined that Applicants are large entity.

Applicants believe that the additional fees, based on the amount of the fee for other than a small entity at the time the filing was paid, listed below are now due:

U.S. Application No. 09/900,766

Filing Utility Patent Application **1203.00**
(Previously paid-including \$40.00 – Assignment Recordation Fee)

TOTAL FEES DUE 1123.00
(AS RESULT OF UNDERPAYMENT AS A SMALL ENTITY)

Pursuant to 37 C.F.R. § 1.28(c) Applicants herewith submit the fees representing the difference between small and large entity status for those fees which were incorrectly submitted. Further status as a small entity in the above-referenced case is hereby withdrawn. Please charge the sum of \$1123.00 to the deposit account of Fulbright & Jaworski L.L.P., Account No. 06-2375, under Order No. 10104199, from which the undersigned is authorized to draw.

If any additional fees are due or missing please also withdraw these fees from the same deposit account. An additional copy of this letter is attached for accounting purposes.

Dated: October 25, 2001

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872
FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5407
(713) 651-5246



FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number	09/900,766
Filing Date	July 6, 2001
First Named Inventor	Goran Forsberg
Examiner Name	Not Yet Assigned
Group Art Unit	1645
Attorney Docket No.	HO-P02188US0

TOTAL AMOUNT OF PAYMENT (\$) 1,123.00

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 06-2375 for Order No. 10104199

Deposit Account Name: Fulbright & Jaworski L.L.P.

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 ☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed

☐ Check ☐ Credit Card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE		Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
SUBTOTAL (1)					(\$) 0.00

2. EXTRA CLAIM FEES

Total Claims	92	-92** =		X		=	0.00
Independent Claims		-3** =		x		=	
Multiple Dependent						=	

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
103	18	203	9	Claims in excess of 20	
102	84	202	42	Independent claims in excess of 3	
104	280	204	140	Multiple dependent claim, if not paid	
109	84	209	42	** Reissue independent claims over original patent	
110	18	210	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES		Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify)					1,123.00
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3)					(\$) 0.00

SUBMITTED BY		Complete (if applicable)	
Name (print/type)	Melissa W. Acosta	Registration No. (Attorney/Agent)	45,872
Signature		Telephone	(713) 651-5407
		Date	October 25, 2001

Fee Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as FIRST CLASS MAIL, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 25, 2001 Signature: (Staci Harris)